As our company grows, so has our QA organization. As we wade through drug development, we are unsure of when QA oversight truly begins. We feel that we have a grasp of QA oversight during clinical work, beginning with Phase 1, but what about pre-clinical activities? What, if any, does QA oversight look like during the pre-clinical phase? I have millions of questions, from batch documentation review to the need for Quality Agreements with GLP labs, etc.